ClinConnect ClinConnect Logo
Search / Trial NCT05709197

The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Jan 24, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Randomized Controlled Trial Prospective Studies Braun Anastomosis Braun Enteroenterostomy

ClinConnect Summary

This clinical trial, called REMBRANDT, is looking at whether adding an extra connection, known as a 'Braun anastomosis,' to the standard surgery for pancreatic cancer can help patients avoid a common issue called delayed gastric emptying. Delayed gastric emptying means that the stomach takes longer than usual to empty its contents, which can be uncomfortable and affect recovery. The trial is actively recruiting participants who are over 18 years old and will be undergoing open pancreatoduodenectomy, a surgery that removes part of the pancreas and is often necessary for pancreatic disease.

To participate, individuals need to be able to read and understand Dutch, as the study materials will be in that language. Some people may not be eligible if they have had certain previous surgeries, are pregnant, or have specific health conditions that might affect their digestive system. Participants in this trial can expect to receive standard care along with the additional surgical connection, and their progress will be monitored to see if this approach helps improve their recovery after surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Undergoing open pancreatoduodenectomy
  • Provided informed consent
  • Age over 18 years
  • Exclusion Criteria:
  • Insufficient control of the Dutch language to read the patient information and to fill out the questionnaires in Dutch hospitals
  • Previous bariatric surgery (such as Roux-en-Y gastric bypass, gastric sleeve)
  • Pregnancy
  • Bowel motility disorders
  • Minimally invasive pancreatoduodenectomy
  • Gastric outlet syndrome

About Radboud University Medical Center

Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.

Locations

Amsterdam, , Netherlands

Leiden, , Netherlands

Rotterdam, , Netherlands

Eindhoven, , Netherlands

Nieuwegein, , Netherlands

Enschede, , Netherlands

Nijmegen, , Netherlands

Leeuwarden, , Netherlands

Maastricht, , Netherlands

Amsterdam, , Netherlands

Zwolle, , Netherlands

Groningen, , Netherlands

Patients applied

0 patients applied

Trial Officials

Martijn WJ Stommel, MD, PhD

Principal Investigator

Radboud University Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials